About Tumor necrosis factor ligand superfamily member 13
Tumor necrosis factor ligand superfamily member 13 (TNFSF13) is a protein
from Homo sapiens identified by UniProt accession
O75888, 250 residues long.
MolForge cross-references it against 0 known binders and
398 disease associations.
Target properties
| Protein name | Tumor necrosis factor ligand superfamily member 13 |
| UniProt accession | O75888 |
| Gene | TNFSF13 |
| Organism | Homo sapiens |
| Length | 250 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (398)
Diseases linked to this target (Open Targets).
- total blood protein measurement · score 0.52
- sex hormone-binding globulin measurement · score 0.37
- IGA glomerulonephritis · score 0.35
- serum non-albumin protein measurement · score 0.29
- lupus nephritis · score 0.29
- blood protein measurement · score 0.28
- high density lipoprotein cholesterol measurement · score 0.27
- alcohol consumption measurement · score 0.27
- serum albumin measurement · score 0.23
- albumin:globulin ratio measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75888-F1 | alphafold | PREDICTED | 81.16 | — |
Amino-acid sequence (250 residues)
MPASSPFLLA PKGPPGNMGG PVREPALSVA LWLSWGAALG AVACAMALLT QQTELQSLRR EVSRLQGTGG PSQNGEGYPW QSLPEQSSDA LEAWENGERS RKRRAVLTQK QKKQHSVLHL VPINATSKDD SDVTEVMWQP ALRRGRGLQA QGYGVRIQDA GVYLLYSQVL FQDVTFTMGQ VVSREGQGRQ ETLFRCIRSM PSHPDRAYNS CYSAGVFHLH QGDILSVIIP RARAKLNLSP HGTFLGFVKL
Explore Tumor necrosis factor ligand superfamily member 13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets